Form 4: Moderna President Stephen Hoge Reports Stock Transactions

Moderna's President, Stephen Hoge, reports the acquisition and disposal of company stock and derivative securities, including transactions related to restricted stock units.

Summary

• On February 27, 2025, Stephen Hoge, President of Moderna, engaged in transactions involving Moderna's common stock and restricted stock units.
• Hoge acquired 5,746 shares of common stock through the conversion of restricted stock units.
• Simultaneously, Hoge disposed of 2,779 shares to cover tax obligations at a price of $33.58 per share.
• Following these transactions, Hoge directly owns 1,450,076 shares of Moderna common stock.
• Hoge also has indirect ownership through Valhalla, LLC (4,116 shares) and a trust (151,933 shares).
• The reported transactions also involve restricted stock units, with 17,241 units remaining after the reported transaction.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is a common practice for publicly traded companies. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading activities.
• Similar filings are made by executives at companies like Pfizer, BioNTech, and Johnson & Johnson, detailing their stock transactions.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the change in ownership, but the amounts are relatively small compared to the total outstanding shares.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Moderna, MRNA, Stephen Hoge, Form 4, Stock Transaction, Restricted Stock Units, Beneficial Ownership, Insider Trading